Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline

Drake, W. M, Stiles, C E, Bevan, J S, Karavitaki, N, Trainer, P J, Rees, Dafydd, Richardson, T I, Baldeweg, S E, Stojanovic, N, Murray, R D, Toogood, A A, Martin, N M, Vaidya, B, Han, T S, Steeds, R P, Baldeweg, F C, Sheikh, U E, Kyriakakis, N, Parasuraman, S, Taylor, L, Butt, N and Anyiam, S 2016. A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. Journal of Clinical Endocrinology & Metabolism 101 (11) , pp. 4189-4194. 10.1210/jc.2016-2224

[img]
Preview
PDF - Accepted Post-Print Version
Download (226kB) | Preview

Abstract

CONTEXT Uncertainty exists whether the long-term use of ergot-derived dopamine agonist (DA) drugs for the treatment of hyperprolactinemia may be associated with clinically significant valvular heart disease; and whether current regulatory authority guidelines for echocardiographic screening are clinically appropriate. OBJECTIVE: To provide follow-up echocardiographic data on a previously described cohort of patients treated with DA for lactotrope pituitary tumors; and to explore possible associations between structural and functional valve abnormalities with the cumulative dose of drug used. DESIGN: Follow-up echocardiographic data were collected from a proportion of our previously reported cohort of patients; all had received continuous DA therapy for at least 2 years in the intervening period. Studies were performed according to British Society of Echocardiography minimum standards for adult transthoracic echocardiography. Generalised estimating equations with backward selection were used to determine odds ratios of valvular heart abnormalities according to tertiles of cumulative cabergoline dose, using the lowest tertile as the reference group. SETTING: Thirteen centers of secondary/tertiary endocrine care across the United Kingdom. RESULTS: There were 192 patients (81 males; median age, 51 years; interquartile range [IQR], 42–62). Median (IQR) cumulative cabergoline doses at the first and second echocardiograms were 97mg (20–377) and 232mg (91–551) respectively. Median (IQR) duration of uninterrupted cabergoline therapy between echocardiograms was 34 months (24–42). No associations were observed between cumulative doses of dopamine agonist used and the age-corrected prevalence of any valvular abnormality. CONCLUSION: This large UK follow-up study does not support a clinically significant association between the use of DA for the treatment of hyperprolactinemia and cardiac valvulopathy - See more at: http://press.endocrine.org/doi/10.1210/jc.2016-2224#sthash.amhpCAmP.dpuf

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Neuroscience and Mental Health Research Institute (NMHRI)
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Uncontrolled Keywords: cabergoline, hyperprolactinemia, cardiac valvulopathy
Publisher: The Endocrine Society
ISSN: 0021-972X
Date of First Compliant Deposit: 23 September 2016
Date of Acceptance: 24 August 2016
Last Modified: 05 Jun 2017 05:32
URI: http://orca.cf.ac.uk/id/eprint/94561

Citation Data

Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics